Search Results

search

Search Filters

Organization
Vera Therapeutics
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 22, 2024 16:05 ET | Vera Therapeutics
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted...
VERA_Thumbnail.jpg
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
November 18, 2024 08:00 ET | Vera Therapeutics
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024 16:05 ET | Vera Therapeutics
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting...
VERA_Thumbnail.jpg
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
November 11, 2024 08:00 ET | Vera Therapeutics
Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024 16:05 ET | Vera Therapeutics
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024 08:00 ET | Vera Therapeutics
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024 08:00 ET | Vera Therapeutics
Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN)...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
October 29, 2024 20:21 ET | Vera Therapeutics
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
October 28, 2024 17:37 ET | Vera Therapeutics
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Figure 1.
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 26, 2024 19:30 ET | Vera Therapeutics
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the...